W L Drew

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Highly quantitative serological detection of anti-cytomegalovirus (CMV) antibodies
    Peter D Burbelo
    Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Virol J 6:45. 2009
  2. ncbi CMV retinitis screening and treatment in a resource-poor setting: three-year experience from a primary care HIV/AIDS programme in Myanmar
    Nini Tun
    California Pacific Medical Center, San Francisco, USA
    J Int AIDS Soc 14:41. 2011
  3. ncbi Absence of activation of CMV by blood transfusion to HIV-infected, CMV-seropositive patients
    W Lawrence Drew
    University of California, San Francisco, Mount Zion Medical Center, California 94115, USA
    Transfusion 43:1351-7. 2003
  4. ncbi Is combination antiviral therapy for CMV superior to monotherapy?
    W Lawrence Drew
    UCSF Mount Zion Medical Center, University of California San Francisco, 1600 Divisadero Street, Box 1629, San Francisco, CA 94115, USA
    J Clin Virol 35:485-8. 2006
  5. ncbi Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet
    W Lawrence Drew
    UCSF Mount Zion Medical Center, University of California, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Clin Virol 37:124-7. 2006
  6. ncbi Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients
    W Lawrence Drew
    UCSF Mount Zion Medical Center, University of California and the Blood Centers of the Pacific, USA
    Transfusion 43:309-13. 2003
  7. ncbi Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients
    W Lawrence Drew
    University of California, San Francisco, UCSF Medical Center at Mount Zion, San Francisco, California 94115, USA
    Curr Opin Infect Dis 20:408-11. 2007
  8. ncbi Cytomegalovirus (CMV) resistance to antivirals
    W L Drew
    Department of Laboratory Medicine, UCSF Mt Zion Medical Center, San Francisco, CA, USA
    Am J Transplant 1:307-12. 2001
  9. ncbi Cytomegalovirus glycoprotein B groups in human immunodeficiency virus-infected patients with incident retinitis
    W Lawrence Drew
    Mount Zion Medical Center, University of California, San Francisco, CA 94115, USA
    J Infect Dis 186:114-7. 2002
  10. ncbi Cytomegalovirus resistance testing: pitfalls and problems for the clinician
    W Lawrence Drew
    UCSF Medical Center at Mount Zion, University of California, San Francisco, 94115, USA
    Clin Infect Dis 50:733-6. 2010

Collaborators

Detail Information

Publications23

  1. ncbi Highly quantitative serological detection of anti-cytomegalovirus (CMV) antibodies
    Peter D Burbelo
    Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Virol J 6:45. 2009
    ..Currently, there is a need for improved quantitative serological tests to document seropositivity with high sensitivity and specificity...
  2. ncbi CMV retinitis screening and treatment in a resource-poor setting: three-year experience from a primary care HIV/AIDS programme in Myanmar
    Nini Tun
    California Pacific Medical Center, San Francisco, USA
    J Int AIDS Soc 14:41. 2011
    ..Prior to this programme, CMV retinitis was not routinely examined for, or treated, in Myanmar...
  3. ncbi Absence of activation of CMV by blood transfusion to HIV-infected, CMV-seropositive patients
    W Lawrence Drew
    University of California, San Francisco, Mount Zion Medical Center, California 94115, USA
    Transfusion 43:1351-7. 2003
    ....
  4. ncbi Is combination antiviral therapy for CMV superior to monotherapy?
    W Lawrence Drew
    UCSF Mount Zion Medical Center, University of California San Francisco, 1600 Divisadero Street, Box 1629, San Francisco, CA 94115, USA
    J Clin Virol 35:485-8. 2006
    ..The combination is frequently used when resistance to either drug is suspected...
  5. ncbi Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet
    W Lawrence Drew
    UCSF Mount Zion Medical Center, University of California, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Clin Virol 37:124-7. 2006
    ..The cytomegalovirus (CMV) UL97 inhibitor drug maribavir (MBV) is undergoing clinical antiviral trials...
  6. ncbi Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients
    W Lawrence Drew
    UCSF Mount Zion Medical Center, University of California and the Blood Centers of the Pacific, USA
    Transfusion 43:309-13. 2003
    ..To explain this residual risk, evidence of cell-free viremia was sought in seroconverting and seroprevalent blood donors and seroconverting transfusion recipients by means of a plasma-based assay for CMV DNA...
  7. ncbi Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients
    W Lawrence Drew
    University of California, San Francisco, UCSF Medical Center at Mount Zion, San Francisco, California 94115, USA
    Curr Opin Infect Dis 20:408-11. 2007
    ..To review new developments in PCR technology as they apply to detecting cytomegalovirus viremia and pneumonia, recent advances in detecting CMV resistance to antivirals and assays of specific CMV lymphocyte function...
  8. ncbi Cytomegalovirus (CMV) resistance to antivirals
    W L Drew
    Department of Laboratory Medicine, UCSF Mt Zion Medical Center, San Francisco, CA, USA
    Am J Transplant 1:307-12. 2001
    ..Factors that favor the development of clinical and in vitro antiviral resistance are discussed. Finally, approaches to altering antiviral therapy as resistance develops are outlined...
  9. ncbi Cytomegalovirus glycoprotein B groups in human immunodeficiency virus-infected patients with incident retinitis
    W Lawrence Drew
    Mount Zion Medical Center, University of California, San Francisco, CA 94115, USA
    J Infect Dis 186:114-7. 2002
    ..These rates were similar among case patients and control subjects and were similar by risk group. The CMV gB2 genotype is not a major determinant of retinitis pathogenicity but appears to be highly prevalent among HIV-infected patients...
  10. ncbi Cytomegalovirus resistance testing: pitfalls and problems for the clinician
    W Lawrence Drew
    UCSF Medical Center at Mount Zion, University of California, San Francisco, 94115, USA
    Clin Infect Dis 50:733-6. 2010
    ..The indications for such testing and the contraindications are discussed, as are the interpretation of results and the evidence of cross-resistance between antivirals...
  11. ncbi Emergence of drug-resistant cytomegalovirus retinitis in the contralateral eyes of patients with AIDS treated with ganciclovir
    Yumi Imai
    Francis I. Proctor Foundation for Research in Ophthalmology and Department of Ophthalmology, University of California at San Francisco, 95 Kirkham Street, San Francisco, CA 94143-0944, USA
    J Infect Dis 189:611-5. 2004
    ..023; Fisher's exact test)...
  12. ncbi Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir
    W L Drew
    Clinical Microbiology and Infectious Diseases, University of California at San Francisco Mt Zion Medical Center, San Francisco, CA, USA
    J Infect Dis 179:1352-5. 1999
    ..Since IC50s for clinical isolates increased proportionately with treatment duration, it is likely that viral resistance would be more frequent with longer treatment...
  13. ncbi Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding
    Jacob P Lalezari
    Quest Clinical Research, San Francisco, California, USA
    Antimicrob Agents Chemother 46:2969-76. 2002
    ..9 to 3.7 log(10) PFU/ml among the four regimens evaluated for anti-HCMV activity. 1263W94 was generally well tolerated; taste disturbance was the most frequently reported adverse event over the 28-day dosing period...
  14. ncbi High dose oral ganciclovir treatment for cytomegalovirus retinitis
    Jacob P Lalezari
    Quest Clinical Research, 2300 Sutter Street, Suite 202 San Francisco, CA 94115, USA
    J Clin Virol 24:67-77. 2002
    ..Median time to progression of CMV retinitis is 12-20 days shorter with oral compared to IV ganciclovir maintenance, likely due to the limited oral bioavailability of ganciclovir...
  15. ncbi Utility of DNA microarrays for detection of viruses in acute respiratory tract infections in children
    Charles Y Chiu
    Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA
    J Pediatr 153:76-83. 2008
    ..To assess the utility of a panviral DNA microarray platform (Virochip) in the detection of viruses associated with pediatric respiratory tract infections (RTIs)...
  16. ncbi Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus
    Sunwen Chou
    Medical and Research Services, Veterans Affairs Medical Center, and Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon 97201, USA
    J Infect Dis 188:32-9. 2003
    ..This study significantly increases the number of confirmed CMV pol resistance mutations, at both conserved and nonconserved loci, with implications for molecular mechanisms and the genotypic diagnosis of antiviral resistance...
  17. ncbi CMV DNA is rarely detected in healthy blood donors using validated PCR assays
    John D Roback
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Transfusion 43:314-21. 2003
    ..NAT of blood components for CMV DNA has been proposed to further reduce the risks of TT-CMV. However, large-scale studies to determine the utility of validated CMV NAT assays for donor screening have not been reported...
  18. ncbi Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients
    Jennifer E Marfori
    Medical and Research Services, VA Medical Center and Oregon Health and Science University, Portland, OR, USA
    J Clin Virol 38:120-5. 2007
    ..We report on two allogeneic stem cell transplant recipients who developed cytomegalovirus disease associated with new viral mutations that conferred antiviral drug resistance...
  19. ncbi Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir
    Sunwen Chou
    Medical and Research Services, VA Medical Center, Portland, OR 97201, USA
    J Infect Dis 185:162-9. 2002
    ..Low drug levels resulting from oral GCV therapy may predispose the virus to the initial selection of these low-grade UL97 resistance mutations and to later accumulation of other mutations and greater resistance...
  20. ncbi Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic
    David Heiden
    Department of Ophthalmology and Pacific Vision Foundation, California Pacific Medical Center, San Francisco, California, United States of America
    PLoS Med 4:e334. 2007
  21. ncbi Characterization of viral agents causing acute respiratory infection in a San Francisco University Medical Center Clinic during the influenza season
    Janice K Louie
    Viral and Rickettsial Disease Laboratory, California Department of Health Services, Richmond, CA 94804, USA
    Clin Infect Dis 41:822-8. 2005
    ..With use of polymerase chain reaction (PCR) and a centrifugation-enhanced viral culture method, we characterized the viruses causing acute respiratory infection in adults during an influenza season...
  22. ncbi The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections
    John D Roback
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
    Transfus Med Rev 20:45-56. 2006
    ..Because PCT is a technology that targets nucleic acids, it also offers a proactive process for the inactivation of a broad range of viral, bacterial, and protozoan pathogens in addition to CMV...
  23. ncbi I wish to comment on several points in the recent "Guidelines"
    W Lawrence Drew
    J Clin Virol 33:79. 2005